Celgene Corporation (NASDAQ:CELG) registered a 1.87% increase, still its new closing price is 22.11% up from the company’s 1 year high of 127.00.It posted 0.85% gains in previous 5 sessions and is now the subject of 4 analysts who together assign a hold rating on stock. 1 of Wall Street analysts have an underperform rating; the 0 sells versus 12 buy or better ratings. The 29 stock analysts following this company have an average price target at $140.12, with individual PT in the $91.00-$162.00 range. The shares moved at $113.62, implying that brokerage firms see shares gaining about 16.88% in twelve months time.

Celgene Corporation (CELG) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a -1.84% fall year to date. A See remarks at Celgene Corporation (CELG) offloaded shares in a transaction closed on Tuesday November 22, 2016. VESSEY RUPERT sold 2,500 shares in the company at $123.18 each and collected $307,001 in proceeds. VESSEY RUPERT now owns 1,285 shares in the company after this transaction. A See remarks in the company, PEHL MICHAEL F., disclosed a transaction on Thursday November 10, 2016 that ended up generating $2,669,000 from the sale of 22,052 shares at $121.04 per share.

Celgene Corporation (NASDAQ:CELG) Upcoming Results on Tap

Celgene Corporation will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $1.63 in that period. Sales during the quarter are predicted to arrive at $3.05 billion.

Earnings surprise history: Last quarter, the company posted approximately $2.98 billion in revenue and EPS of $1.61. The mean forecast was for $3.02 billion and $1.59 a share, respectively. One quarter earlier, revenue for the stock was at $2.98 billion, with earnings at $1.58/share.

Celgene Corporation (CELG) Brokerage Update

Celgene Corporation (CELG) is in Standpoint Research’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by Standpoint Research, according to news reported on Wednesday November 09, 2016.Another important research note was issued by JP Morgan on Thursday October 01, 2015.The firm upgraded CELG to Overweight from Neutral. Over the last six months and over the last three months, the shares of Celgene Corporation (CELG), have changed 2.12% and 15.46%, respectively.